Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis

摘要

The use of the angiotensin II receptor antagonist telmisartan (I) (or its salt) and the 3-hydroxy-2-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin (II) is claimed in the production of medicaments (A) for the treatment or prophylaxis of cardiovascular, cardiopulmonary or renal diseases. Independent claims are included for corresponding treatment methods and pharmaceutical compositions. ACTIVITY : Cardiant; Vasotropic; Hepatotropic; Hypotensive; Antilipemic; Antiarteriosclerotic; Antiasthmatic; Antiinflammatory; Antidiabetic; Cerebroprotective; Antianginal; Cytostatic; Antibacterial; Immunosuppressive; Vulnerary; Osteopathic; Neuroprotective; Nootropic. MECHANISM OF ACTION : Angiotensin II receptor antagonist; HMG-CoA reductase inhibitor; Peroxisome proliferator activated receptor-gamma (PPAR-gamma ) regulating gene expression inducer; Matrix metalloproteinase MMP-9 expression controller; Cytokine CD40L antagonist.